Works Cited

1. Cepoiu M, McCusker J, Cole MG, Sewitch M, Belzile E, Ciampi A. Recognition of depression by non-psychiatric physicians: a systematic literature review and meta-analysis. J Gen Int Med. 2007;23(1):25-36.

2. Lewy C, Sells CW, Gilhooly J, McKelvey R. Adolescent depression: evaluating pediatric residents' knowledge, confidence, and interpersonal skills using standardized patients. Acad Psychiatry. 2009;33(5):389-393.

3. Jameson JP, Blank MB. Diagnosis and treatment of depression and anxiety in rural and nonrural primary care: national survey results. Psychiatr Serv. 2010;61(6):624-627.

4. Raue PJ, Schulberg HC, Heo M, Klimstra S, Bruce ML. Patients' depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study. Psychiatr Serv. 2009;60(3):337-343.

5. Young HN, Bell RA, Epstein RM, Feldman MD, Kravitz RL. Physicians' shared decision-making behaviors in depression care.Arch Intern Med. 2008;168(13):1404-1408.

6. National Institute of Mental Health. Mental Health: Statistics. Available at https://www.nimh.nih.gov/health/statistics/index.shtml. Last accessed July 24, 2017.

7. Agency for Healthcare Research and Quality. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: Executive Summary. Available at http://www.effectivehealthcare.ahrq.gov/ehc/products/7/61/Antidepressants_Executive_Summary.pdf. Last accessed July 24, 2017.

8. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):629-640.

9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.

10. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160-174.

11. Strine TW, Mokdad AH, Balluz LS, et al. Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance System. Psychiatr Serv. 2008;59:1383-1390.

12. Chapman DP, Perry GS, Strine TW. The vital link between chronic disease and depressive disorders. Prev Chronic Dis. 2005;2:A14.

13. Centers for Disease Control and Prevention. QuickStats: prevalence of current depression among persons aged ≥12 years, by age group and sex—United States, National Health and Nutrition Examination Survey, 2007–MMWR. 2012;60(51):1747.

14. Halverson JL, Bhalla RN, Moraille-Bhalla P, Andrew LB, Leonard RC. Depression. Available at http://emedicine.medscape.com/article/286759-overview. Last accessed July 24, 2017.

15. National Center for Health Statistics. Health, United States, 2011: With Special Feature on Socioeconomic Status and Health. Hyattsville, MD: National Center for Health Statistics; 2012.

16. Pratt LA, Brody DJ. Depression in the United States household population, 2005–2006. NCHS Data Brief. 2008;7:1-8.

17. Centers for Disease Control and Prevention. Depression is Not a Normal Part of Growing Older. Available at https://www.cdc.gov/aging/mentalhealth/depression.htm. Last accessed July 24, 2017.

18. Birrer RB, Vemuri SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Phys. 2004;69(10):2375-2382.

19. Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005;(119):1-8.

20. Vesga-López O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65(7):805-815.

21. Mitchell J, Trangle M, Degnan B, et al., for the Institute for Clinical Systems Improvement. Adult Depression in Primary Care. 16th ed. Available at https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_behavioral_health_guidelines/depression/. Last accessed July 24, 2017.

22. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Washington, DC: American Psychiatric Publishing, Inc.; 2010.

23. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-1475.

24. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155-162.

25. Beck A, Crain AL, Solberg LI, et al. Severity of depression and magnitude of productivity loss. Ann Fam Med. 2011;9:305-311.

26. Han D, Wang EC. Remission from depression: a review of venlafaxine clinical and economic evidence. Pharmacoeconomics. 2005;23(6):567-581.

27. Toney SD. Identifying and managing depression in women. J Manag Care Pharm. 2007;13(9 suppl A):S16-S22.

28. Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22(6):363-373.

29. Fletcher JM. Adolescent depression and educational attainment: results using sibling fixed effects. Health Econ. 2010;19(7):855-871.

30. Shepard DS, Gurewich D, Lwin AK, Reed GA Jr, Silverman MM. Suicide and suicidal attempts in the united states: costs and policy implications. Suicide Life Threat Behav. 2016;46(3):352-362.

31. Centers for Disease Control and Prevention. Depression. Available at https://www.cdc.gov/mentalhealth/basics/mental-illness/depression.htm. Last accessed July 24, 2017.

32. U.S. Department of Health and Human Services, Office of the Surgeon General, and National Action Alliance for Suicide Prevention. 2012 National Strategy for Suicide Prevention: Goals and Objectives for Action. Washington, DC: U.S. Department of Health and Human Services; 2012.

33. Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27(8):959-985.

34. Mahendran R, Yap HL. Clinical practice guidelines for depression. Singapore Med J. 2005;46(11):610-615.

35. Onyike CU, Crum RM, Lee HB, Lyketsos CG, Eaton WW. Is obesity associated with major depression? Results from the third national health and nutrition examination survey. Am J Epidemiol. 2003;158(12):1139-1147.

36. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358(1):55-68.

37. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008;65(11):1029-1038.

38. Mitchell J, Trangle M, Degnan B, et al. Adult Depression in Primary Care. Bloomington, MN: Institute for Clinical Systems Improvement; 2013.

39. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65(5):513-520.

40. Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010;167(8):934-941.

41. Hirschfeld RMA. Clinical importance of long-term antidepressant treatment. Br J Psychiatry. 2001;179(suppl):S4-S8.

42. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55(12):1128-1132.

43. Kim KH, Lee SM, Paik JW, Kim NS. The effects of continuous antidepressant treatment during the first 6 months on relapse or recurrence of depression. J Affect Disord. 2011;132(1-2):121-129.

44. NIMH/NIH Consensus Development Conference Statement. Mood disorders: pharmacologic prevention of recurrences. Am J Psychiatry. 1985;142(4):469-476.

45. Hasselmann HW. Ketamine as antidepressant? Current state and future perspectives. Curr Neuropharmacol. 2014;12(1):57-70.

46. Rosenblat JD, McIntyre RS, Alves GS, Fountoulakis KN, Carvalho AF. Beyond monoamines-novel targets for treatment-resistant depression: a comprehensive review. Curr Neuropharmacol. 2015;13(5):636-655.

47. Nasrallah HA. 10 recent paradigm shifts in the neurobiology and treatment of depression. Curr Psych. 2015;14(2).

48. Agency for Healthcare Research and Quality. Healthcare Horizon Scanning System Potential High-Impact Interventions: Priority Area 05: Depression and Other Mental Health Disorders. Rockville, MD: Agency for Healthcare Research and Quality; 2015.

49. Niciu MJ, Ionescu DF, Richards EM, Zarate CA Jr. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2014;121(8):907-924.

50. Köhler O, Krogh J, Mors O, Benrosc ME. Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol. 2016;14(7):732-742.

51. Weber D, O'Brien K. Cancer and cancer-related fatigue and the interrelationships with depression, stress, and inflammation.Journal of Evidence-Based Complementary & Alternative Medicine. 2017;22(3).

52. Heim C, Plotsky PM, Nemeroff CB. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology. 2004;29(4):641-648.

53. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;1141:105-130.

54. Kalinichev M, Easterling KW, Holtzman SG. Long-lasting changes in morphine-induced locomotor sensitization and tolerance in Long-Evans mother rats as a result of periodic postpartum separation from the litter: a novel model of increased vulnerability to drug abuse? Neuropsychopharmacology. 2003;28(2):317-328.

55. Pryce CR, Feldon J. Long-term neurobehavioural impact of the postnatal environment in rats: manipulations, effects and mediating mechanisms. Neurosci Biobehav Rev. 2003;27(1-2):57-71.

56. Goodman A. The neurobiological development of addiction. Psychiatr Times. 2009;26(9):1-14.

57. Danese A, Baldwin JR. Hidden wounds? Inflammatory links between childhood trauma and psychopathology. Annu Rev Psychol. 2017;68:517-544.

58. Klinkman MS. The role of algorithms in the detection and treatment of depression in primary care. J Clin Psychiatry. 2003;64(suppl2):19-23.

59. Sotelo JL, Nemeroff CB. Depression as a systemic disease. Personalized Medicine in Psychiatry. 2017;1-2:11-25.

60. Pace TW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163(9):1630-1633.

61. Drysdale AT, Grosenick L, Downar J, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23(1):28-38.

62. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374(9690):609-619.

63. Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. disease burden and principles of care. Can J Psychiatry. 2016;61(9):510-523.

64. Siu A, U.S. Preventive Services Task Force. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(4):380-387.

65. U.S. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. Washington, DC: U.S. Department of Veterans Affairs; 2016

66. Bosanquet K, Bailey D, Gilbody S, et al. Diagnostic accuracy of the Whooley questions for the identification of depression: a diagnostic meta-analysis. BMJ Open. 2015;5(12):e008913.

67. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2015;29:459-525.

68. Simon GE, Rutter CM, Peterson D, et al. Does response on the PHQ-9 Depression Questionnaire predict subsequent suicide attempt or suicide death? Psychiatr Serv. 2013;64(12):1195-1202.

69. Trangle M, Gursky J, Haight R, et al. Adult Depression in Primary Care. Bloomington, MN: Institute for Clinical Systems Improvement; 2016.

70. National Institute for Health and Clinical Excellence. Depression: The Treatment and Management of Depression in Adults. London: The British Psychological Society and the Royal College of Psychiatrists; 2010.

71. Michigan Quality Improvement Consortium. Primary Care Diagnosis and Management of Adults with Depression. Southfield, MI: Michigan Quality Improvement Consortium; 2014.

72. Snowden A, White CA, Christie Z, Murray E, McGowan C, Scott R. The clinical utility of the distress thermometer: a review.Br J Nurs. 2011;20(4):220-227.

73. Bow JN, Flens JR, Gould JW. MMPI-2 and MCMI-III in forensic evaluations: a survey of psychologists. J Forensic Psychol Pract. 2010;10(1):37-52.

74. Centers for Disease Control and Prevention. Understanding Suicide: Fact Sheet. Available at https://www.cdc.gov/violenceprevention/pdf/suicide_factsheet-a.pdf. Last accessed July 24, 2017.

75. Center for Substance Abuse Treatment. Substance Abuse and Suicide Prevention: Evidence and ImplicationsA White Paper. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2008.

76. Hensley PL, Clayton PJ. Bereavement-Related Depression. Available at http://www.psychiatrictimes.com/articles/bereavement-related-depression. Last accessed July 24, 2017.

77. Shear MK, Reynolds CF 3rd, Simon NM, et al. Optimizing treatment of complicated grief: a randomized clinical trial. JAMA Psychiatry. 2016;73(7):685-694.

78. Miranda J, Schoenbaum M, Sherbourne C, Duan N, Wells K. Effects of primary care depression treatment on minority patients' clinical status and employment. Arch Gen Psychiatry. 2004;61(8):827-834.

79. Muñoz RF, Mendelson T. Toward evidence-based interventions for diverse populations: the San Francisco General Hospital prevention and treatment manuals. J Consult Clin Psychol. 2005;73(5):790-799.

80. Karasz A. Cultural differences in conceptual models of depression. Soc Sci Med. 2005;60(7):1625-1635.

81. Nadeem E, Lange JM, Miranda J. Mental health care preferences among low-income and minority women. Arch Womens Ment Health. 2008;11(2):93-102.

82. Lesser IM, Castro DB, Gaynes BN, et al. Ethnicity/race and outcome in the treatment of depression: results from STAR*D.Med Care. 2007;45(11):1043-1051.

83. Anglin DM, Alberti PM, Link BG, Phelan JC. Racial differences in beliefs about the effectiveness and necessity of mental health treatment. Am J Comm Psychol. 2008;42(1-2):17-24.

84. Menselson T, Rehkopf DH, Kubzansky LD. Depression among Latinos in the United States: a meta-analytic review. J Consulting Clin Psychol. 2008;76(3):355-366.

85. Schmaling KB, Hernandez DV. Problem-solving treatment for depression among Mexican Americans in primary care. J Health Care Poor Underserved. 2008;19(2):466-477.

86. Tiwari SK, Wang JL. Ethnic differences in mental health service use among White, Chinese, South Asian and South East Asian populations living in Canada. Soc Psychiatry Psychiatr Epidemiol. 2008;43(11):866-871.

87. Ialongo N, McCreary BK, Pearson JL, et al. Major depression disorder in a population of urban, African-American young adults: prevalence, correlates, comorbidity and unmet mental health service need. J Affect Disord. 2004;79(1-3):127-136.

88. Robinson L, Smith M, Segal J. Depression in Older Adults: Recognizing the Signs and Getting the Right Treatment. Available at https://www.helpguide.org/articles/depression/depression-in-older-adults.htm. Last accessed July 24, 2017.

89. Kessler RC, Birnbaum H, Bromet E, Hwang I, Sampson N, Shahly V. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychol Med. 2010;40(2):225-237.

90. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61(4):1-118.

91. Substance Abuse and Mental Health Services Administration. The Treatment of Depression in Older Adults: Depression and Older Adults: Key Issues. Rockville, MD: Center for Mental Health Services, Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services; 2011.

92. Bryant C. Anxiety and depression in old age: challenges in recognition and diagnosis. Int Psychogeriatr. 2010;22(4):511-513.

93. Fischer LR, Wei F, Solberg LI, Rush WA, Heinrich RL. Treatment of elderly and other adult patients for depression in primary care. J Am Geriatr Soc. 2003;51(11): 1554-1562.

94. Mitchell AJ, Rao S, Vaze A. Do primary care physicians have particular difficulty identifying late-life depression? A meta-analysis stratified by age. Psychother Psychosom. 2010;79(5):285-94.

95. Law J, Laidlaw K, Peck D. Is depression viewed as an inevitable consequence of age? The "understandability phenomenon" in older people. Clinical Gerontologist. 2010;33(3):194-209.

96. Uncapher H, Arean PA. Physicians are less willing to treat suicidal ideation in older patients. J Am Geriatr Soc. 2000;48:188-192.

97. Park M, Unützer J. Geriatric depression in primary care. Psychiatr Clin North Am. 2011;34(2):469-487.

98. Stromberg R, Wernering E, Aberg-Wistedt A, Furhoff A-K, Johansson S-E, Backlund LG. Screening and diagnosing depression in women visiting GPs' drop in clinic in primary health care. BMC Fam Pract. 2008;9:34-43.

99. Sharp LK, Lipsky MS. Screening for depression across the lifespan: a review of measures for use in primary care settings. Am Fam Phys. 2002;66(6):1001-1009.

100. Gotlib IH, Hammen CL (eds). Handbook of Depression. 2nd ed. New York, NY: Guilford Press; 2010.

101. Richardson LP, McCauley E, Grossman DC, et al. Evaluation of the Patient Health Questionnaire-9 Item for detecting major depression among adolescents. Pediatrics. 2010;126(6):1117-1123.

102. Kovacs M. Children's Depression Inventory. North Tonawanda, NY: Multi-Health System; 1992.

103. Suicide Prevention Resource Center. Suicide Risk and Prevention for Lesbian, Gay, Bisexual, and Transgender Youth. Available at http://www.sprc.org/resources-programs/suicide-risk-and-prevention-lesbian-gay-bisexual-and-transgender-youth-1. Last accessed July 24, 2017.

104. Ryan C, Huebner D, Diaz RM, Sanchez J. Family rejection as a predictor of negative health outcomes in white and Latino lesbian, gay, and bisexual young adults. Pediatrics. 2009;123(1):346-352.

105. Mustanski BS, Garofalo R, Emerson EM. Mental health disorders, psychological distress, and suicidality in a diverse sample of lesbian, gay, bisexual, and transgender youths. Am J Pub Health. 2010;100(12):2426-2432.

106. Khouzam HR. Depression: guidelines for effective primary care. Part I: diagnosis. Psychiatr Times Consult. 2007;47(8):1-6.

107. Nierenberg AA, Trivedi MH, Fava M, et al. Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. J Psychiatr Res. 2007;41(3-4):214-221.

108. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62(10):1097-1106.

109. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105.

110. Nock MK, Hwang I, Sampson NA, Kessler RC. Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(8):868-876.

111. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.

112. Nierenberg AA, Katz J, Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am. 2007;30(1):13-29.

113. CareFirst Blue Cross Blue Shield. Clinical Practice Guidelines For Depression In Adults In The Primary Care Setting. Available at https://provider.carefirst.com/carefirst-resources/provider/pdf/depression-guidelines-bok0023.pdf. Last accessed July 24, 2017.

114. Zimmerman M, Galione J. Psychiatrists' and nonpsychiatrist physicians' reported use of the DSM-IV criteria for major depressive disorder. J Clin Psychiatry. 2010;71(3):235-238.

115. Houle J, Gascon-Depatie M, Bélanger-Dumontier G, Cardinal C. Depression self-management support: a systematic review. Patient Educ Couns. 2013;91(3):271-279.

116. Dimidjian S, Barrera M Jr, Martell C, Muñoz RF, Lewinsohn PM. The origins and current status of behavioral activation treatments for depression. Annu Rev Clin Psychol. 2011;7:1-38.

117. Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of depression: a meta-analysis. Clin Psychol Rev. 2007;27(3):318-326.

118. Mazzucchelli T, Kane R, Rees C. Behavioral activation treatments for depression in adults: a meta-analysis and review. Cin Psychol Sci Prac. 2009;16(4):383-411.

119. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.

120. O'Connor AM, Bennett C, Stacey D, et al. Do patient decision aids meet effectiveness criteria of the international patient de cision aid standards collaboration? A systematic review and meta-analysis. Med Decis Making. 2007;27(5):554-574.

121. Arnow BA, Blasey C, Williams LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatry. 2015;172(8):743-750.

122. Harald B, Gordon P. Meta-review of depressive subtyping models. J Affect Disord. 2012;139(2):126-140.

123. Joyce PR, McKenzie JM, Carter JD, et al. Temperament, character and personality disorders as predictors of response to interpersonal psychotherapy and cognitive behavioural therapy for depression. Br J Psychiatry. 2007;190:503-508.

124. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A. 2003;100(24):14293-14296.

125. Ward EC. Examining differential treatment effects for depression in racial and ethnic minority women: a qualitative systematic review. J Natl Med Assoc. 2007;99(3):265-274.

126. Lanouette NM, Folsom DP, Sciolla A, Jeste DV. Psychotropic medication nonadherence among United States Latinos: a comprehensive literature review. Psychiatr Serv. 2009;60(2):157-174.

127. Rothe EM, Pumariega AJ, Rogers KM. Cultural Aspects of the Pharmacological Treatment of Depression: Factors Affecting Minority and Youth. Available at http://www.psychiatrictimes.com/articles/cultural-aspects-pharmacological-treatment-depression-factors-affecting-minority-and-youth. Last accessed July 24, 2017.

128. Unützer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288(22):2836-2845.

129. Areán PA, Ayalon L, Hunkeler E, et al. Improving depression care for older, minority patients in primary care. Med Care. 2005;43(4):381-390.

130. Williams JW Jr, Noël PH, Cordes JA, Ramirez G, Pignone M. Is this patient clinically depressed? JAMA. 2002;287(9):1160-1170.

131. Manber R, Arnow B, Blasey C, et al. Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication. Psychol Med. 2003;33(4):693-702.

132. Leichsenring F, Rabung S, Leibing E. The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry. 2004;61(12):1208-1216.

133. de Jonghe F, Hendriksen M, Van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. Brit J Psychiatry. 2004;185:37-45.

134. Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006;74(4):658-670.

135. Kwan BM, Dimidjian S, Rizvi SL. Treatment preference, engagement, and clinical improvement in pharmacotherapy versus psychotherapy for depression. Behav Res Ther. 2010;48(8):799-804.

136. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Washington, DC: American Psychiatric Association; 2010.

137. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851-855.

138. Bockting CL, Hollon SD, Jarrett RB, Kuyken W, Dobson K. A lifetime approach to major depressive disorder: the contributions of psychological interventions in preventing relapse and recurrence. Clin Psychol Rev. 2015;41:16-26.

139. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40(1):41-50.

140. van der Voort TY, Seldenrijk A, van Meijel B, et al. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J Clin Psychiatry. 2015;76(6):e809-e814.

141. Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol. 2016;19(2):pyv076.

142. Bondolfi G, Jermann F, der Linden MV, et al. Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: replication and extension in the Swiss health care system. J Affect Disord. 2010;122(3):224-231.

143. Sonawalla SB. Citalopram in the maintenance treatment of major depressive disorder. J Clin Psychiatry. 2001;62(12):993.

144. Berwian IM, Seifritz WE, Huys QJM. Predicting relapse after antidepressant withdrawal: a systematic review. Psychol Med. 2017;47(3):426-437.

145. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374(9690):609-619.

146. Rost K, Nutting P, Smith JL, Elliott CE, Dickinson M. Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care. BMJ. 2002;325(7370):934-937.

147. Schoenbaum M, Unützer J, McCaffrey D, Duan N, Sherbourne C, Wells KB. The effects of primary care depression treatment on patients' clinical status and employment. Health Serv Res. 2002;37(5):1145-1158.

148. Goldapple K, Segal Z, Garson C, et al. Modulation of cortical-limbic pathways in major depression: treatment specific effects of cognitive behavior therapy. Arch Gen Psychiatry. 2004;61(1):34-41.

149. McIntyre RS. Evidence-based treatment of bipolar disorder, bipolar depression, and mixed features. J Fam Pract. 2015;64(6 Suppl):S16-S23.

150. Bell AC, D'Zurilla TJ. Problem-solving therapy for depression: a meta-analysis. Clin Psychol Rev. 2009;29(4):348-353.

151. Nezu AM, Nezu CM, Perri MG. Problem-Solving Therapy for Depression: Theory Research and Clinical Guidelines. New York, NY: Wiley; 1989.

152. Areán PA, Raue P, Mackin RS, Kanellopoulos D, McCulloch C, Alexopoulos GS. Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction. Am J Psychiatry. 2010;167:1391-1398.

153. Warmerdam L, van Straten A, Jongsma J, Twisk J, Cuijpers P. Online cognitive behavioral therapy and problem-solving therapy for depressive symptoms: exploring mechanisms of change. J Behav Ther Exp Psychiatry. 2010;41(1):64-70.

154. Furukawa TA, Weitz ES, Tanaka S, et al. Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data meta-analysis of pill-placebo-controlled trials. Br J Psychiatry. 2017;210(3):190-196.

155. Trivedi MH, Kleiber BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry. 2001;62(suppl 6):22-29.

156. Bostwick JM. A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. Mayo Clin Proc. 2010;85(6):538-550.

157. U.S. Department of Veteran Affairs. Clinical Practice Guideline: Management of Major Depressive Disorder. Washington, DC: U.S. Department of Defense; 2009.

158. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540-560.

159. Kaser M, Zaman R, Sahakian BJ. Cognition as a treatment target in depression. Psychol Med. 2017;47(6):987-989.

160. Stahl SM. Mixed-up about how to diagnose and treat mixed features in major depressive episodes. CNS Spectr. 2017;22(2):111-115.

161. Caraci F, Leggio GM, Salomone S, Drago F. New drugs in psychiatry: focus on new pharmacological targets. F1000Res. 2017;6:397.

162. Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother. 2014;15(17):2525-2542.

163. Sansone RA, Sansone LA. Emergency Psychiatry Update. Available at https://www.ahcmedia.com/articles/134475-emergency-psychiatry-update. Last accessed July 24, 2017.

164. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737-748.

165. Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry. 2009;194(6):483-490.

166. Amsterdam JD. Monoamine oxidase inhibitor therapy in severe and resistant depression. Psychiatric Ann. 2006;36(9):607-613.

167. Fowler JS, Logan J, Azzaro AJ, et al. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010;35(3):623-631.

168. U.S. Food and Drug Administration. FDA Approves Emsam (Selegiline) as First Drug Patch for Depression. Available at https://wayback.archive-it.org/7993/20170113023146/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108607.htm. Last accessed July 24, 2017.

169. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3):226-247.

170. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003;9(1):97-140.

171. Santarsieri D. Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015;4:212290.

172. Padala PR, Burke WJ, Bhatia SC, Petty F. Treatment of apathy with methylphenidate. J Neuropsychiatry Clin Neurosci. 2007;19:81-83.

173. Hardy SE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother. 2009;7(1):34-59.

174. Ishizaki J, Mimura M. Dysthymia and apathy: diagnosis and treatment. Depression Res Treatment. 2011;893905.

175. LexiComp Online. Available at http://online.lexi.com. Last accessed July 24, 2017.

176. Lam RW, Parikh SV, Michalak EE, Dewa CS, Kennedy SH. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry. 2015;27(2):142-149.

177. McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29(3):243-259.

178. Kamenov K, Cabello M, Coenen M, Ayuso-Mateos JL. How much do we know about the functional effectiveness of interventions for depression? A systematic review. J Affect Disord. 2015;188:89-96.

179. Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf. 2015;14(8):1291-1304.

180. McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1-7.

181. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900-909.

182. Madhoo M, Keefe RS, Roth RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014;39(6):1388-1398.

183. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959-965.

184. Rizvi SJ, Kennedy SH. Management strategies for SSRI-induced sexual dysfunction. J Psychiatry Neurosci. 2013;38(5):E27-E28.

185. Balon R. SSRI-associated sexual dysfunction. Am J Psychiatry. 2006;163(9):1504-1509.

186. American Urological Association. Clinical Guidelines: Erectile Dysfunction. Available at http://www.auanet.org/guidelines/erectile-dysfunction-(2005-reviewed-and-validity-confirmed-2011). Last accessed July 24, 2017.

187. Möller HJ, Baldwin DS, Goodwin G, et al. Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci. 2008;258(suppl 3):3-23.

188. Leon AC, Solomon DA, Li C, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry. 2011;72(5):580-586.

189. Narayan V, Haddad PM. Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria. J Psychopharmacol. 2011;25(3):306-313.

190. U.K. Medicines and Healthcare Products Regulatory Agency. Selective Serotonin Reuptake Inhibitors (SSRIS) and Serotonin and Noradrenaline Reuptake Inhibitors (SNRIS): Use and Safety. Available at https://www.gov.uk/government/publications/ssris-and-snris-use-and-safety. Last accessed July 24, 2017.

191. Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms: telephone calls to a national medication helpline. J Affect Disord. 2006;95(1):129-133.

192. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72-81.

193. Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol. 2013;4:45.

194. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363-368.

195. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24(3):183-197.

196. Valuck RJ, Orton HD, Libby AM. Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study. J Clin Psychiatry. 2009;70(8):1069-1077.

197. Yasui-Furukori N, Hashimoto K, Tsuchimine S, et al. Characteristics of escitalopram discontinuation syndrome: a preliminary study. Clin Neuropharmacol. 2016;39(3):125-127.

198. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomized study. J Psychopharmacol. 2008;22(3):330-332.

199. Cortes JA, Radhakrishnan R. A case of amelioration of venlafaxine-discontinuation "brain shivers" with atomoxetine. Prim Care Companion CNS Disord. 2013;15(2).

200. Kjernisted K, McIntosh D. Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag. 2007;3(1):59-69.

201. Petit J, Sansone RA. A case of interdose discontinuation symptoms with venlafaxine extended release. Prim Care Companion CNS Disord. 2011;13(5):PCC.11l01140.

202. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959-965.

203. Uher R. Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry. 2011;19(3):109-124.

204. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353.

205. Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry. 2012;57(12):782-788.

206. Sato S, Yeh TL. Challenges in treating patients with major depressive disorder: the impact of biological and social factors. CNS Drugs. 2013;27 Suppl 1:S5-S10.

207. IsHak WW, Greenberg JM, Balayan K, et al. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry. 2011;19(5):229-239.

208. Werneke U. Risk management of nutritional supplements in chronic illness: the implications for the care of cancer and depression. Proc Nutr Soc. 2007;66(4):483-492.

209. Morgan AJ, Jorm AF. Self-help interventions for depressive disorders and depressive symptoms: a systematic review. Ann Gen Psychiatry. 2008;7:13-36.

210. Linde K, Mulrow CD. St. John's wort for depression. Cochrane Database Syst Rev. 2000;(2):CD000448.

211. Linde K, Berner M, Egger M, Mulrow C. St John's wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry. 2005;186:99-107.

212. Kasper S, Gastpar M, Müller WE, et al. Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. Eur Arch Psychiatry Clin Neurosci. 2008;258(1):59-63.

213. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):118-127.

214. Charrois TL, Sadler C, Vohra S; American Academy of Pediatrics Provisional Section on Complementary, Holistic, and Integrative Medicine. Complementary, holistic, and integrative medicine: St. John's wort. Pediatr Rev. 2007;28(2):69-72.

215. Sarris J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother Res. 2007;21(8):703-716.

216. Freire RC, Hallak JE, Crippa JA, Nardi AE. New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opin Pharmacother. 2011;12(9):1419-1428.

217. Zheng H, Zhang L, Li L, et al. High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1189-1195.

218. Karege F, Perroud N, Burkhardt S, et al. Alterations in phosphatidylinositol 3-kinase activity and PTEN phosphatase in the prefrontal cortex of depressed suicide victims. Neuropsychobiology. 2011;63(4):224-231.

219. Gianfranco C, Vittorio U, Silvia B, Francesco D. Myo-inositol in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2011;26(7):526-530.

220. Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. 1995;152(5):792-794.

221. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. 1996;153(9):1219-1221.

222. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001;21(3):335-339.

223. Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997;7(2):147-155.

224. Zheng H, Zhang L, Li L, et al. High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1189-1195.

225. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroundi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. BMC Complement Altern Med. 2004:4:12.

226. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):439-442.

227. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med. 2004;4:12.

228. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res. 2005;19(2):148-151.

229. Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine. 2006;13(9-10):607-611.

230. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol. 2005;97(2):281-284.

231. Kruger TH, Wollmer MA. Depression: an emerging indication for botulinum toxin treatment. Toxicon. 2015;107(Pt A):154-157.

232. Finzi E, Rosenthal NE. Treatment of depression with onabotulinum toxin A: a randomized, double-blind, placebo controlled trial.J Psychiatr Res. 2014;52:1-6.

233. Wollmer MA, Kalak N, Jung S, et al. Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial. Front Psychiatry. 2014;5:36.

234. Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry. 2016;173(2):174-183.

235. Berlim MT, Fleck MP, Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med. 2008;40(2):149-159.

236. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Patient adherence in the treatment of depression. Br J Psychiatry. 2002;180:104-109.

237. Bollini P, Pampallona S, Kupelnick B, Tibaldi G, Munizza C. Improving compliance in depression: a systematic review of narrative reviews. J Clin Pharm Ther. 2006;31(3):253-260.

238. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy.Med Care. 1995;33(1):67-74.

239. Tierney JG Jr. Treatment-resistant depression: managed care considerations. J Manag Care Pharm. 2007;13(6 Suppl a):S2-S7.

240. Vergouwen AC, Bakker A, Katon WJ, Verheij TJ, Koerselman F. Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry. 2003;64(12):1415-1420.

241. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-1530.

242. Sharma V, Khan M, Smith A. A closer look at treatment resistant depression: is it due to a bipolar diathesis? J Affect Disord. 2005;84(2-3):251-257.

243. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66(suppl 8):5-12.

244. Schatzberg AF, Rush AJ, Arnow BA, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry. 2005;62(5):513-520.

245. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164(5):739-752.

246. Taylor DJ, Walters HM, Vittengl JR, Krebaum S, Jarrett RB. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence? J Affect Disord. 2010;123(1-3):181-187.

247. Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice: an update of the agency for health care policy and research practice guidelines. Arch Gen Psychiatry. 1998;55(12):1121-1127.

248. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.

249. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48(4):303-307.

250. Preskorn SH, Beber JH, Faul JC, Hirschfeld R. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry. 1990;147(4):532.

251. Henssler J, Bschor T, Baethge C. Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients. Can J Psychiatry. 2016;61(1):29-43.

252. Han C, Wang SM, Kwak KP, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study. J Psychiatr Res. 2015;66-67:84-94.

253. Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008;69(1):87-94.

254. Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(6):561-569.

255. DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(9):1057-1064.

256. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101-1107.

257. Trivedi MH, Cutler AJ, Richards C, et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.J Clin Psychiatry. 2013;74(8):802-809.

258. Cusin C, Iovieno N, Iosifescu DV, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013;74(7):e636-e641.

259. Pae CU. Agomelatine: a new option for treatment of depression? Expert Opin Pharmacother. 2014;15(4):443-447.

260. Ménard C, Hodes GE, Russo SJ. Pathogenesis of depression: insights from human and rodent studies. Neuroscience. 2016;321:138-162.

261. Mathews DC, Henter ID, Zarate CA. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs. 2012;72(10):1313-1333.

262. Kaster MP, Moretti M, Cunha MP, Rodrigues AL. Novel approaches for the management of depressive disorders. Eur J Pharmacol. 2016;771:236-240.

263. DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015;1345:47-58.

264. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry. 2005;162(4):656-662.

265. Leppämäki SJ, Partonen TT, Hurme J, Haukka JK, Lönnqvist JK. Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptoms and serum lipids. J Clin Psychiatry. 2002;63(4):316-321.

266. Jorm AF, Christensen H, Griffiths KM, Rodgers B. Effectiveness of complementary and self-help treatments for depression. Med J Aust. 2002;176(10 suppl):S84-S95.

267. Prasko J, Horacek J, Klaschka J, Kosova J, Ondrackova I, Sipek J. Bright light therapy and/or imipramine for inpatients with recurrent non-seasonal depression. Neuro Endocrinol Lett. 2002;23(2):109-113.

268. Epperson CN, Terman M, Terman JS, et al. Randomized clinical trial of bright-light therapy for antepartum depression: preliminary findings. J Clin Psychiatry. 2004;65(3):421-425.

269. Oren DA, Wisner KL, Spinelli M, et al. An open trial of morning light therapy for treatment of antepartum depression. Am J Psychiatry. 2002;159(4):666-669.

270. Benedetti F, Colombo C, Pontiggia A, Bernasconi A, Florita M, Smeraldi E. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J Clin Psychiatry. 2003;64(6):648-653.

271. Even C, Schröder CM, Friedman S, Rouillon F. Efficacy of light therapy in nonseasonal depression: a systematic review. J Affect Disord. 2008;108(1-2):11-23.

272. Baeken C, De Raedt R, Bossuyt A, et al. The impact of HF-rTMS treatment on serotonin(2A) receptors in unipolar melancholic depression. Brain Stimul. 2011;4(2):104-111.

273. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull. 2003;65:193-207.

274. Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: perspectives from affective neuroscience. Annu Rev Psychol. 2002;53:545-574.

275. Perrin JS, Merz S, Bennett DM, et al. Electroconvulsive therapy reduces frontal cortical connectivity in severe depressive disorder. Proc Natl Acad Sci U S A. 2012;109(14):5464-5468.

276. Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. neurostimulation treatments. Can J Psychiatry. 2016;61(9):561-575.

277. Brunoni AR, Boggio PS, De Raedt R, et al. Cognitive control therapy and transcranial direct current stimulation for depression: a randomized, double-blinded, controlled trial. J Affect Disord. 2014;162:43-49.

278. Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087-1206.

279. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244-253.

280. Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology. 2013;38(12):2467-2474.

281. Heijnen WT, Birkenhäger TK, Wierdsma AI, van den Broek WW. Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: a meta-analysis. J Clin Psychopharmacol. 2010;30(5):616-619.

282. Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry. 2015;76(10):1374-1384.

283. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568-577.

284. Sackeim HA, Prudic J, Fuller R, Keilp J, Lavori PW, Olfson M. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology. 2007;32(1):244-254.

285. Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology. 2006;31(7):1345-1355.

286. Nahas Z, Teneback C, Chae JH, et al. Serial vagus nerve stimulation functional MRI in treatment-resistant depression. Neuropsychopharmacology. 2007;32(8):1649-1660.

287. Hatton KW, McLarney JT, Pittman T, Fahy BG. Vagal nerve stimulation: overview and implications for anesthesiologists.Anesth Analg. 2006;103(5):1241-1249.

288. Rush AJ, Siefert SE. Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. Exp Neurol. 2009;219(1):36-43.

289. Aaronson ST, Sears P, Ruvuna F, et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry. 2017;174(7):640-648.

290. Rabins P, Appleby BS, Brandt J, et al. Scientific and ethical issues related to deep brain stimulation for disorders of mood, behavior, and thought. Arch Gen Psychiatry. 2009;66(9):931-937.

291. Malone DA Jr, Dougherty DD, Rezai AR, et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009;65(4):267-275.

292. Appleby BS, Duggan PS, Regenberg A, Rabins PV. Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: a meta-analysis of ten years' experience. Mov Disord. 2007;22(12):1722-1728.

293. Wassermann EM, Lisanby SH. Therapeutic application of repetitive transcranial magnetic stimulation: a review. Clin Neurophysiol. 2001;112(8):1367-1377.

294. Schutter DJLG, van Honk J. A framework for targeting alternative brain regions with repetitive transcranial magnetic stimulation in the treatment of depression. J Psychiatry Neurosci. 2005;30(2):91-97.

295. Health Quality Ontario. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression. Available at http://www.hqontario.ca/Evidence-to-Improve-Care/Health-Technology-Assessment/Reviews-And-Recommendations/Repetitive-Transcranial-Magnetic-Stimulation-for-Treatment-Resistant-Depression. Last accessed July 24, 2017.

296. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587-596.

297. Klein MM, Treister R, Raij T, et al. Transcranial magnetic stimulation of the brain: guidelines for pain treatment research. Pain. 2015;156(9):1601-1614.

298. Lam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. Can J Psychiatry. 2008;53(9):621-631.

299. Bretlau LG, Lunde M, Lindberg L, Undén M, Dissing S, Bech P. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. Pharmacopsychiatry. 2008;41(2):41-47.

300. Garay RP, Zarate CA Jr, Charpeaud T, et al. Investigational drugs in recent clinical trials for treatment-resistant depression.Expert Rev Neurother. 2017;17(6):593-609.

301. Jaso BA, Niciu MJ, Iadarola ND, et al. Therapeutic modulation of glutamate receptors in major depressive disorder. Curr Neuropharmacol. 2017;15(1):57-70.

302. Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46(7):1459-1472.

303. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399-405.

304. Moskal JR. Glutamatergic-based rapid acting antidepressants: the link to synaptic plasticity. Curr Neuropharmacol. 2017;15(1):2.

305. Burgdorf J, Zhang XL, Weiss C, et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience. 2015;308:202-211.

306. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49-57.

307. Henter ID, de Sousa RT, Gold PW, et al. Mood therapeutics: novel pharmacological approaches for treating depression. Expert Review of Clinical Pharmacology. 2017; [Epub ahead of print].

308. Ghanizadeh A, Hedayati A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depress Anxiety. 2013;30(11):1084-1088.

309. Gougol A, Zareh-Mohammadi N, Raheb S, et al. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: a double-blind placebo-controlled trial. J Psychopharmacol. 2015;29(5):575-581.

310. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235.

311. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016; 3(7):619-627.

312. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180.

313. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197.

314. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898-906.

315. Mian AI. Depression in pregnancy and the postpartum period: balancing adverse effects of untreated illness and treatment risks.J Psychiatr Pract. 2005;11(6):389-396.

316. Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166(5):557-566.

317. Pearlstein T. Perinatal depression: treatment options and dilemmas. J Psychiatry Neurosci. 2008;33(4):302-318.

318. Nylen KJ, O'Hara MW, Brock R, Moel J, Gorman L, Stuart S. Predictors of the longitudinal course of postpartum depression following interpersonal psychotherapy. J Consult Clin Psychol. 2010;78(5):757-763.

319. O'Hara MW. Postpartum depression: what we know. J Clin Psychol. 2009;65(12):1258-1269.

320. Freeman MP, Davis M, Sinha P, Wisner KL, Hibbeln JR, Gelenberg AJ. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord. 2008;110(1-2):142-148.

321. Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80(1):18-27.

322. Thormahlen GM. Paroxetine use during pregnancy: is it safe? Ann Pharmacother. 2006;40(10):1834-1837.

323. Austin MP. To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects. Psychol Med. 2006;36(12):1663-1670.

324. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 2007;29(5):918-926.

325. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-587.

326. Ferreira E, Carceller AM, Agogué C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119(1):52-59.

327. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 2005;193(6):2004-2009.

328. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499-507.

329. Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #18: use of antidepressants in nursing mothers. Breastfeeding Med. 2008;3(1):44-52.

330. Eberhard-Gran M, Eskild A, Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs. 2006;20(3):187-198.

331. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(6):1066-1078.

332. di Scalea TL, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol. 2009;52(3):483-497.

333. Pisani AR, Murrie DC, Silverman MM. Reformulating suicide risk formulation: from prediction to prevention. Acad Psychiatry. 2016;40(4):623-629.

334. Khazem LR, Anestis MD. Thinking or doing? An examination of well-established suicide correlates within the ideation-to-action framework. Psychiatry Res. 2016;245:321-326.

335. Klonsky ED, Qiu T, Saffer BY. Recent advances in differentiating suicide attempters from suicide ideators. Current Opinion in Psychiatry. 2017;30:15-20.

336. Glenn CR, Nock MK. Improving the short-term prediction of suicidal behavior. Am J Prev Med. 2014;47(3 Suppl 2):S176-S180.

337. Serafini G, Pompili M, Belvederi Murri M, et al. The effects of repetitive transcranial magnetic stimulation on cognitive performance in treatment-resistant depression: a systematic review. Neuropsychobiology. 2015;71(3):125-139.

338. Large M, Galletly C, Myles N, et al. Known unknowns and unknown unknowns in suicide risk assessment: evidence from meta-analyses of aleatory and epistemic uncertainty. B J Psych Bull. 2017;41:160-163.

339. American Psychiatric Association. Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors. Available at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/suicide.pdf. Last accessed July 24, 2017.

340. Pokorny AD. Prediction of suicide in psychiatric patients: report of a prospective study. Arch Gen Psychiatry. 1983;40:249-257.

341. Carter G, Milner A, McGill K, et al. Predicting suicidal behaviours using clinical instruments: systematic review and meta-analysis of positive predictive values for risk scales. Br J Psychiatry. 2017;210(6):387-395.

342. Chan MK, Bhatti H, Meader N, et al. Predicting suicide following self-harm: systematic review of risk factors and risk scales. Br J Psychiatry. 2016;209:277-283.

343. Nielssen O, Wallace D, Large M. Pokorny's complaint: the insoluble problem of the overwhelming number of false positives generated by suicide risk assessment. B J Psych Bull. 2017;41:18-20.

344. Large M, Kaneson M, Myles N, et al. Meta-analysis of longitudinal cohort studies of suicide risk assessment among psychiatric patients: heterogeneity in results and lack of improvement over time. PLoS ONE. 2016;11:e0156322.

345. Murray D. Is it time to abandon suicide risk assessment? B J Psych Open. 2016;2:e1-e2.

346. Chung DT, Ryan CJ, Hadzi-Pavlovic D, et al. Suicide rates after discharge from psychiatric facilities. JAMA Psychiatry. 2017; [Epub ahead of print].

347. Olfson M, Marcus SC, Bridge JA. Focusing suicide prevention on periods of high risk. JAMA. 2014;311:1107-1108.

348. Large M, Galletly C, Myles N, et al. Known unknowns and unknown unknowns in suicide risk assessment: evidence from meta-analyses of aleatory and epistemic uncertainty. B J Psych Bull. 2017;41:160-163.

349. American Psychiatric Association. APA Practice Guidelines for the Psychiatric Evaluation of Adults. 3rd ed. Arlington, VA: American Psychiatric Publishing; 2016.

350. Haney EM, O'Neil ME, Carson S, et al. Suicide Risk Factors and Risk Assessment Tools: A Systematic Review. Washington, DC: Department of Veterans Affairs; 2012.

351. U.S. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide. Washington, DC: U.S. Department of Veterans Affairs; 2013.

352. Glenn JJ, Werntz AJ, Slama SJ, et al. Suicide and self-injury-related implicit cognition: a large-scale examination and replication.J Abnorm Psychol. 2017;126:199-211.

353. McDowell AK, Lineberry TW, Bostwick JM. Practical suicide-risk management for the busy primary care physician. Mayo Clin Proc. 2011;86(8):792-800.

354. Ramchand R, Kelly TF. Can Access to Data Prevent Army Suicides? Identifying Optimal Response Strategies for Army Leaders. Santa Monica, CA.: RAND Corporation; 2016.

355. Isometsa ET, Lonnqvist JK. Suicide attempts preceding completed suicide. Br J Psychiatry. 1998;173:531-535.

356. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry. 1997;170:205-228.

357. Kegler SR, Stone DM, Holland KM. Trends in suicide by level of urbanization—United States, 1999–2015. MMWR. 2017;66:270-273.

358. American Foundation for Suicide Prevention. Suicide Statistics. Available at http://afsp.org/about-suicide/suicide-statistics. Last accessed July 24, 2017.

359. Ludwig B, Roy B, Wang Q, et al. The life span model of suicide and its neurobiological foundation. Front Neurosci. 2017;11:74.

360. Drapeau CW, McIntosh JL. Suicide 2015: Official Final Data. Available at http://www.suicidology.org/resources/facts-statistics. Last accessed July 24, 2017.

361. American Association of Suicidology. Press Release: Musician Chris Cornell Dies at 52. Available at http://www.suicidology.org/Portals/14/docs/Misc/ChrisCornellPressRelease.pdf?ver=2017-05-18-225007-070. Last accessed July 24, 2017.

362. Web-Based Injury Statistics Query and Reporting System. Fatal Injury Queries: Fatal Injury Reports, National and Regional, 1999–2015. Available at http://webappa.cdc.gov/sasweb/ncipc/mortrate10_us.html. Last accessed July 24, 2017.

363. Suicide Prevention Resource Center. Racial and Ethnic Disparities. Available at http://www.sprc.org/racial-ethnic-disparities. Last accessed July 24, 2017.

364. Piscopo K, Lipari RN, Cooney J, Glasheen C. Suicidal thoughts and behavior among adults: Results from the 2015 National Survey on Drug Use and Health. NSDUH Data Review. 2016;9.

365. van Heeringen K, Mann JJ. The neurobiology of suicide. Lancet Psychiatry. 2014;1(1):63-72.

366. Joiner TE Jr, Brown JS, Wingate LR. The psychology and neurobiology of suicidal behavior. Annu Rev Psychol. 2005;56:287-314.

367. Provencal N, Binder EB. The neurobiological effects of stress as contributors to psychiatric disorders: focus on epigenetics. Curr Opin Neurobiol. 2015;30:31-37.

368. Mann JJ, Currier DM. Stress, genetics and epigenetic effects on the neurobiology of suicidal behavior and depression. Eur Psychiatry. 2010;25(5):268-271.

369. Costanza A, D'Orta I, Perroud N, et al. Neurobiology of suicide: do biomarkers exist? Int J Legal Med. 2014;128(1):73-82.

370. Brundin L, Erhardt S, Bryleva EY, Achtyes ED, Postolache TT. The role of inflammation in suicidal behaviour. Acta Psychiatr Scand. 2015;132(3):192-203.

371. Stewart JG, Glenn CR, Esposito EC, et al. Cognitive control deficits differentiate adolescent suicide ideators from attempters. J Clin Psychiatry. 2017;78(6):e614-e621.

372. Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011;131(2):363-370.

373. American Association of Suicidology. College Students and Suicide Fact Sheet 2016. Available at http://www.suicidology.org/Portals/14/Re-Formatted%20College%20Students%20Fact%20Sheet.pdf?ver=2016-11-16-110354-547. Last accessed July 24, 2017.

374. Kann L, Olsen EO, McManus T, et al. Sexual identity, sex of sexual contacts, and health-related behaviors among students in grades 9–12—United States and selected sites, 2015. MMWR. 2016;65(9):1-208.

375. Bouris A, Everett BG, Heath RD, et al. Effects of victimization and violence on suicidal ideation and behaviors among sexual minority and heterosexual adolescents. LGBT Health. 2016;3:153-161.

376. Rieger G, Savin-Williams R. Gender nonconformity, sexual orientation, and psychological well-being. Arch Sex Behav. 2012;41:611-621.

377. Toomey RB, Ryan C, Diaz RM, Card NA, Russell ST. Gender-nonconforming lesbian, gay, bisexual, and transgender youth: School victimization and young adult psychosocial adjustment. Dev Psychol. 2010;46:1580-1589.

378. Ioerger M, Henry KL, Chen PY, et al. Beyond same-sex attraction: gender-variant-based victimization is associated with suicidal behavior and substance use for other-sex attracted adolescents. PLoS One. 2015;10(6):e0129976.

379. Josephson WL, Pepler D. Bullying: a stepping stone to dating aggression? Int J Adolesc Med Health. 2012;24:37-47.

380. Hymel S, Swearer SM. Four decades of research on school bullying: an introduction. Am Psychol. 2015;70:293-299.

381. Starcevic V, Aboujaoude E. Cyberchondria, cyberbullying, cybersuicide, cybersex: "new" psychopathologies for the 21st century? World Psychiatry. 2015;14:1.

382. Messias E, Kindrick K, Castro J. School bullying, cyberbullying, or both: correlates of teen suicidality in the 2011 CDC Youth Risk Behavior Survey. Compr Psychiatry. 2014;55:1063-1068.

383. Campbell-Sills L, Kessler RC, Ursano RJ, et al. Associations of childhood bullying victimization with lifetime suicidal behaviors among new U.S. Army soldiers. Depress Anxiety. 2017; [Epub ahead of print].

384. Hottes TS, Bogaert L, Rhodes AE, et al. Lifetime prevalence of suicide attempts among sexual minority adults by study sampling strategies: a systematic review and meta-analysis. Am J Public Health. 2016;106:e1-e12.

385. Remafedi G. Suicidality in a venue-based sample of young men who have sex with men. J Adolesc Health. 2002;31(4):305-310.

386. Paul JP, Catania J, Pollack L, et al. Suicide attempts among gay and bisexual men: lifetime prevalence and antecedents. Am J Public Health. 2002;92(8):1338-1345.

387. Meyer I. H., Dietrich J., Schwartz S. Lifetime prevalence of mental disorders and suicide attempts in diverse lesbian, gay, and bisexual populations. Res Pract. 2007;97(11):9-11.

388. Barboza GE, Dominguez S, Chance E. Physical victimization, gender identity and suicide risk among transgender men and women. Preventive Medicine Reports. 2016;4:385-390.

389. Bauer GR, Scheim AI, Pyne J, et al. Intervenable factors associated with suicide risk in transgender persons: a respondent driven sampling study in Ontario, Canada. BMC Public Health. 2015;15:525.

390. Kessler RC, Stein MB, Petukhova MV, et al. Predicting suicides after outpatient mental health visits in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). Mol Psychiatry. 2017;22:544-551.

391. Kang HK, Bullman TA, Smolenski DJ, et al. Suicide risk among 1.3 million veterans who were on active duty during the Iraq and Afghanistan wars. Ann Epidemiol. 2015;25(2):96-100.

392. Millner AJ, Lee MD, Nock MK. Describing and measuring the pathway to suicide attempts: a preliminary study. Suicide Life Threat Behav. 2017;47:353-369.

393. Ribeiro JD, Gutierrez PM, Joiner TE, et al. Health care contact and suicide risk documentation prior to suicide death: Results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). J Consult Clin Psychol. 2017;85:403-408.

394. Mustanski B, Liu RT. A longitudinal study of predictors of suicide attempts among lesbian, gay, bisexual, and transgender youth. Arch Sex Behav. 2013;42(3):437-448.

395. World Health Organization. Preventing Suicide in Jails and Prisons. Available at http://www.who.int/mental_health/prevention/suicide/resource_jails_prisons.pdf. Last accessed July 24, 2017.

396. Pompili M, Lester D, Innamorati M, et al. Preventing suicide in jails and prisons: suggestions from experience with psychiatric inpatients. J Forensic Sci. 2009;54(5):1155-1162.

397. Clark DC, Horton-Deutsch SL. Assessment in absentia: the value of the psychological autopsy method for studying antecedents of suicide and predicting future suicides. In: Maris RW, Berman AL, Maltsberger JT, Yufit RI (eds). Assessment and Prediction of Suicide. New York, NY: Guilford Press; 1992: 144-182.

398. Schmidtke A, Schaller S. The role of mass media in suicide prevention. In: Hawton K, van Heeringen K (eds). The International Handbook of Suicideand Attempted Suicide. New York, NY: Wiley; 2000: 675-697.

399. Velting DM, Gould MS. Suicide contagion. In: Maris RW, Silverman MM, Canetto SS (eds). Review of Suicidology. New York, NY: Guilford Press; 2000: 96-136.

400. Zenere EFJ. Suicide clusters and contagion. Principal Leadership. 2009;10(2):12-16.

401. Pirkis J. Suicide and the media. Psychiatry. 2009;8(7):269-271.

402. Yom-Tov E, Fischer SH. The Werther Effect Revisited: Measuring the Effect of News Items on User Behavior. WWW'17 Companion. 2017;4.

403. Young R, Subramanian R, Miles S, et al. Social representation of cyberbullying and adolescent suicide: a mixed-method analysis of news stories. Health Commun. 2016;26:1-11.

404. Najt P, Fusar-Poli P, Brambilla P. Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res. 2011;186(2-3):159-164.

405. Murphy GE. Suicide in Alcoholism. New York, NY: Oxford University Press; 1992.

406. Annenberg Public Policy Center. Holiday-Suicide Link: The Myth Persists. Available at http://www.annenbergpublicpolicycenter.org/holiday-suicide-link-the-myth-persists. Last accessed July 24, 2017.

407. Centers for Disease Control and Prevention. Injury Prevention and Control: Data and Statistics. Available at https://www.cdc.gov/injury/wisqars/index.html. Last accessed July 24, 2017.

408. Fosse R, Ryberg W, Carlsson MK, Hammer J. Predictors of suicide in the patient population admitted to a locked-door psychiatric acute ward. PLoS ONE. 2017;12:e0173958.

409. May AM, Klonsky ED. What distinguishes suicide attempters from suicide ideators? A meta-analysis of potential factors. Clin Psychol Sci Pract. 2016;23:5-20.

410. Millner AJ, Ursano RJ, Hwang I, et al. Lifetime suicidal behaviors and career characteristics among U.S. Army soldiers: results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). Suicide Life Threat Behav. 2017; [Epub ahead of print].

411. Kleiman EM, Turner BJ, Fedor S, et al. Examination of real-time fluctuations in suicidal ideation and its risk factors: results from two ecological momentary assessment studies. J Abnorm Psychol. 2017; [Epub ahead of print].

412. Bender TW. Suicidality and Impulsivity: A Test of the Mediating Role of Painful Experiences [dissertation]. Florida State University Digital Library; 2009.

413. Solomon RL. The opponent-process theory of acquired motivation: the costs of pleasure and benefits of pain. American Psychologist. 1980;35:691-712.

414. Shneidman ES. Perspectives on suicidology: further reflections on suicide and psychache. Suicide Life Treat Behav. 1998;28:245-250.

415. Swannell SV, Martin GE, Page A, et al. Prevalence of nonsuicidal self-injury in nonclinical samples: systematic review, meta-analysis and meta-regression. Suicide Life Threat Behav. 2014;44(3):273-303.

416. Kaess M, Parzer P, Mattern M, et al. Adverse childhood experiences and their impact on frequency, severity, and the individual function of nonsuicidal self-injury in youth. Psychiatry Res. 2013;206(2-3):265-272.

417. Nitkowski D, Petermann F. Non-suicidal self-injury and comorbid mental disorders: a review. Fortschr Neurol Psychiatr. 2011;79(1):9-20.

418. Paul E, Tsypes A, Eidlitz L, et al. Frequency and functions of non-suicidal self-injury: associations with suicidal thoughts and behaviors. Psychiatry Res. 2015;225:276-282.

419. Nakar O, Brunner R, Schilling O, et al. Developmental trajectories of self-injurious behavior, suicidal behavior and substance misuse and their association with adolescent borderline personality pathology. J Affect Disord. 2016;197:231-238.

420. Carroll R, Thomas KH, Bramley K, et al. Self-cutting and risk of subsequent suicide. J Affect Disord. 2016;192:8-10.

421. Brown GK, Green KL. A review of evidence-based follow-up care for suicide prevention. Am J Prev Med. 2014;47(3S2):S209-S215.

422. Glenn CR, Lanzillo EC, Esposito EC, et al. Examining the course of suicidal and nonsuicidal self-injurious thoughts and behaviors in outpatient and inpatient adolescents. J Abnorm Child Psychol. 2017;45(5):971-983.

423. Juurlink DN, et al. Medical illness and the risk of suicide in the elderly. Arch Intern Med. 2004;164:1179-1184.

424. Asmundson GJG, Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety. 2009;26:888-901.

425. Elman I, et al. Pain and suicidality: insights from reward and addiction neuroscience. Prog Neurobiol. 2013;109:1-27.

426. Nadeau SE. Opioids for chronic noncancer pain: to prescribe or not to prescribe—what is the question? Neurology. 2015;85:646-651.

427. Calati R, Laglaoui Bakhiyi C, Artero S, et al. The impact of physical pain on suicidal thoughts and behaviors: meta-analyses.J Psychiatr Res. 2015;71:16-32.

428. Campbell G, Darke S, Bruno R, Degenhardt L. The prevalence and correlates of chronic pain and suicidality in a nationally representative sample. Aust N Z J Psychiatry. 2015;49:803-811.

429. Fishbain DA, Bruns D, Bruns A, et al. The perception of being a burden in acute and chronic pain patients is associated with affirmation of different types of suicidality. Pain Med. 2016;17(3):530-538.

430. Hooley JM, Franklin JC, Nock MK. Chronic pain and suicide: understanding the association. Curr Pain Headache Rep. 2014;18(8):435.

431. Verrocchio MC, Carrozzino D, Marchetti D, et al. Mental pain and suicide: a systematic review of the literature. Front Psychiatry. 2016;7:108.

432. Rizvi SJ, Iskric A, Calati R, Courtet P. Psychological and physical pain as predictors of suicide risk: evidence from clinical and neuroimaging findings. Curr Opin Psychiatry. 2017;30:159-167.

433. Mee S, Bunney BG, Bunney WE, et al. Assessment of psychological pain in major depressive episodes. J Psychiatr Res. 2011;45:1504-1510.

434. Troister T, Holden RR. Factorial differentiation among depression, hopelessness, and psychache in statistically predicting suicidality. Meas Eval Couns Dev. 2013;46:50-63.

435. Flamenbaum R, Holden RR. Psychache as a mediator in the relationship between perfectionism and suicidality. J Couns Psychol. 2007;54(1):51-61.

436. Campos RC, Holden RR. Testing models relating rejection, depression, interpersonal needs, and psychache to suicide risk in nonclinical individuals. J Clin Psychol. 2015;71(10):994-1003.

437. Orbach I, Mikulincer M, Gilboa-Schechtman E, Sirota P. Mental pain and its relationship to suicidality and life meaning. Suicide Life Threat Behav. 2003;33:231-241.

438. Levinger S, Somer E, Holden RR. The importance of mental pain and physical dissociation in youth suicidality. J Trauma Dissociation. 2015;16:322-339.

439. Tillman JG, Clemence AJ, Cree R, et al. The persistent shadow of suicide ideation and attempts in a high-risk group of psychiatric patients: a focus for intervention. Compr Psychiatry. 2017;77:20-26.

440. May AM, Klonsky ED. "Impulsive" suicide attempts: what do we really mean? Pers Dis. 2016;7:293-302.

441. Nock MK, Hwang I, Sampson NA, Kessler RC. Mental disorders, co-morbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15:868-876.

442. Nock MK, Hwang I, Sampson N, et al. Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys. PLoS Med. 2009;6:e1000123.

443. Busch KA, Fawcett J, Jacobs DG. Clinical correlates of inpatient suicide. J Clin Psychiatry. 2003;64:14-19.

444. Iosifescu DV. Maintaining the initial clinical response after ketamine in
bipolar and unipolar depression: an important next-step challenge. J Clin Psychiatry. 2015;76(6):738-740.

445. Cherpitel CJ, Borges GL, Wilcox HC. Acute alcohol use and suicidal behavior: a review of the literature. Alcohol Clin Exp Res. 2004;28(5 Suppl):18S-28S.

446. Borges G, Walters EE, Kessler RC. Associations of substance use, abuse, and dependence with subsequent suicidal behavior. Am J Epidemiol. 2000;151:781-789.

447. Branas CC, Richmond TS, Ten Have TR, Wiebe DJ. Acute alcohol consumption, alcohol outlets, and gun suicide. Subst Use Misuse. 2011;46(13):1592-1603.

448. Powell KE, Kresnow MJ, Mercy JA, et al. Alcohol consumption and nearly lethal suicide attempts. Suicide Life Threat Behav. 2001;32(1 Suppl):30-41.

449. Hufford MR. Alcohol and suicidal behavior. Clin Psychol Rev. 2001;21:797–811.

450. Sher L. Alcohol consumption and suicide. Q J Med. 2006;99:57-61.

451. Aharonovich E, Liu X, Nunes E, Hasin DS. Suicide attempts in substance abusers: effects of major depression in relation to substance use disorders. Am J Psychiatry. 2002;159(9):1600-1602.

452. Preuss UW, Schuckit MA, Smith TL, et al. Comparison of 3190 alcohol-dependent individuals with and without suicide attempts. Alcohol Clin Exp Res. 2002;26:471-477.

453. World Health Organization. Preventing Suicide: A Resource for General Physicians. Available at http://www.who.int/mental_health/media/en/56.pdf. Last accessed July 24, 2017.

454. World Health Organization. Preventing Suicide: A Resource for Primary Health Care Workers. Geneva: World Health Organization Department of Mental Health; 2000.

455. Goldblatt MJ, Ronningstam E, Schechter M, et al. Suicide as escape from psychotic panic. Bull Menninger Clin. 2016;80(2):131-145.

456. Grinshteyn E, Hemenway D. Violent death rates: the US compared with other high-income OECD countries, 2010. Am J Med. 2016;129:266-273.

457. Kposowa A, Hamilton D, Wang K. Impact of firearm availability and gun regulation on state suicide rates. Suicide Life Threat Behav. 2016;46:678-696.

458. American Association of Suicidality. Depression and Suicide Risk. Available at http://www.suicidology.org/Portals/14/docs/Resources/FactSheets/2011/DepressionSuicide2014.pdf. Last accessed July 24, 2017.

459. Mohandie K, Meloy JR, Collins PI. Suicide by cop among officer involved shooting cases. Journal of Forensic Science. 2009;54:456-462.

460. Mohandie K, Meloy JR. Suicide by cop among female subjects in officer involved shooting cases. Journal of Forensic Science. 2011;56:664-668.

461. Suicide Prevention Resource Center and SPAN USA. Charting the Future of Suicide Prevention: A 2010 Progress Review of the National Strategy and Recommendations for the Decade Ahead. Washington, DC: Education Development Center, Inc.; 2010.

462. Pearson JL, Claassen CA, Booth CL, et al. Introduction to the suicide prevention research prioritization task force special supplement. Am J Prev Med. 2014;47(3S2):S102-S105.

463. National Action Alliance for Suicide Prevention. 2015 Progress and Forward Momentum. Available at http://www.ActionAllianceforSuicidePrevention.org. Last accessed July 24, 2017.

464. U.S. Department of Health and Human Services, Office of the Surgeon General. 2012 National Strategy for Suicide Prevention: Goals and Objectives for Action. Washington, DC: U.S. Department of Health and Human Services; 2012.

465. American Association of Suicidology. Survivors of Suicide Fact Sheet. Available at http://www.suicidology.org/Portals/14/docs/Survivors/Loss%20Survivors/Survivors-of-Suicide-Fact-Sheet_2010.pdf?ver=2014-05-07-161555-730. Last accessed July 24, 2017.

466. Jobes DA, Wong SA, Conrad AK, et al. The collaborative assessment and management of suicidality versus treatment as usual: a retrospective study with suicidal outpatients. Suicide and Life-Threatening Behavior. 2005;35:483-497.

467. Griffiths JJ, Zarate Jr CA, Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. Am J Prev Med. 2014;47:S195-S203.

468. Soleimani L, Welch A, Murrough JW. Does ketamine have rapid anti-suicidal ideation effects? Curr Treat Options Psychiatry. 2015;2(4):383-393.

469. Yovell Y, Bar G, Mashiah M, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173(5):491-498.

470. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522-526.

471. Price RB, Iosifescu DV, Murrough JW et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31:335-343.

472. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;1-5.

473. Ballard ED, Lally N, Nugent AC, et al. Neural correlates of suicidal ideation and its reduction in depression. Int J Neuropsychopharmacol. 2014;18.

474. Ionescu DF, Swee MB, Pavone KJ, et al. Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry. 2016;77(6):e719-e725.

475. Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2015;80(6):424-431.

476. Reid WH. Asking the Patient is Not Enough: Suicide Risk Assessment and Management for Emergency and Primary Care Physicians. Available at http://www.reidpsychiatry.com/Asking%20the%20Patient%20Is%20Not%20Enough%20GENERIC%20VERSION%20041417.ppsx. Last accessed July 24, 2017.

477. Resnick PJ. Recognizing that the suicidal patient views you as an "adversary." Current Psychiatry. 2002;1(1):8.

478. Covington D, the Clinical Care and Intervention Task Force. Suicide Care in Systems Framework. Washington, DC: The National Action Alliance for Suicide Prevention; 2012.

479. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 2010;32:403-425.

480. Edwards SJ, Sachmann MD. No-suicide contracts no-suicide agreements, and no-suicide assurances: a study of their nature, utilization, perceived effectiveness, and potential to cause harm. Crisis. 2010;31(6):290-302.

481. National Institute for Health and Care Excellence. Self-Harm in Over 8s: Long-Term Management. Edinburgh: NICE; 2011.

482. Busch K, Clark D, Fawcett J, Kravitz HM. Clinical features of inpatient suicide. Psychiatric Ann. 1993;23:256-262.

483. Erlangsen A, Runeson B, Bolton JM, et al. Association between spousal suicide and mental, physical, and social health outcomes. JAMA Psychiatry. 2017;74(5):456-464.

484. Plemmons G, Hall M, Doupnik S, et al. Hospitalization for suicide ideation or attempt: 2008–2015. Pediatrics. 2018; [Epub ahead of print].

Evidence-Based Practice Recommendations Citations

1. Trangle M, Gursky J, Haight R, et al. Adult Depression in Primary Care. Bloomington, MN: Institute for Clinical Systems Improvement; 2016. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/50406. Last accessed June 22, 2017.

2. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010. Summary retrieved from National Guideline Clearinghouse at https://www.guideline.gov/summaries/summary/24158. Last accessed June 22, 2017.



Privacy Policy
Copyright © 2017 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.